Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

Documenti analoghi

• Beyond BRAFV600E: Investigating the Clinical and Genetic Spectrum of Langerhans Cell Histiocytosis in Children
  di: Xue Tang, et al.
  Pubblicazione: (2024)
• BRAF‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy
  di: Chan‐Juan Wang, et al.
  Pubblicazione: (2024)
• Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures
  di: Kevin Bielamowicz, et al.
  Pubblicazione: (2024)
• Treatment of pediatric refractory or relapsed Epstein–Barr virus‐associated hemophagocytic syndrome with PD‐1 inhibitors
  di: Shu‐Yi Guo, et al.
  Pubblicazione: (2024)
• Clinical outcomes of pomalidomide‐based and daratumumab‐based therapies in patients with relapsed/refractory multiple myeloma: A real‐world cohort study in China
  di: Xiaoyan Han, et al.
  Pubblicazione: (2024)